COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02183090
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to investigate the pharmacokinetics and tolerability of an intramuscular 15 mg meloxicam injection in comparison to the 15 mg oral tablet

Condition or disease Intervention/treatment Phase
Healthy Drug: Meloxicam ampoule Drug: Meloxicam tablet Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Tolerability of a Single 15mg Meloxicam Dose Injected Intramuscularly Compared to a Single Oral 15 mg Meloxicam Tablet in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study.
Study Start Date : November 1998
Actual Primary Completion Date : December 1998

Resource links provided by the National Library of Medicine

Drug Information available for: Meloxicam

Arm Intervention/treatment
Experimental: Meloxicam ampoule Drug: Meloxicam ampoule
Active Comparator: Meloxicam tablet Drug: Meloxicam tablet

Primary Outcome Measures :
  1. AUC0-inf (total area under the plasma drug concentration-time curve) [ Time Frame: up to 96 hours after drug administration ]
  2. Cmax (Maximum drug plasma concentration) [ Time Frame: up to 96 hours after drug administration ]
  3. tmax (Time to achieve Cmax) [ Time Frame: up to 96 hours after drug administration ]

Secondary Outcome Measures :
  1. AUC0-t (Total area under the plasma drug concentration-time curve from time of administration to the time of the last quantifiable drug concentration) [ Time Frame: up to 96 hours after drug administration ]
  2. λz (apparent terminal elimination rate constant) [ Time Frame: up to 96 hours after drug administration ]
  3. t1/2 (apparent terminal elimination half-life) [ Time Frame: up to 96 hours after drug administration ]
  4. MRTtot (Mean residence time) [ Time Frame: up to 96 hours after drug administration ]
  5. CL/f (Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration) [ Time Frame: up to 96 hours after drug administration ]
  6. Vz/f (Apparent volume of distribution during the terminal phase λz following extravascular administration) [ Time Frame: up to 96 hours after drug administration ]
  7. Change from baseline in vital signs (pulse rate, systolic and diastolic blood pressure) [ Time Frame: Baseline, days 1-5 of each treatment period ]
  8. Change from baseline in laboratory parameters [ Time Frame: Baseline, days 1-2 and 5 of each treatment period ]
  9. Number of patients with adverse events [ Time Frame: up to 72 hours after day 5 of each treatment period ]
  10. Tolerability of the intramuscular injection [ Time Frame: before and 4 and 24 hours after application of study drug ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects as determined by results of screening
  • Written informed consent in accordance with Good Clinical Practice and local legislation
  • Age ≥ 18 and ≤ 50 years
  • Broca > - 20% and < + 20%

Exclusion Criteria:

  • Any findings of the medical examination (including laboratory, blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastro-intestinal tract ( except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
  • Chronic or relevant acute infections
  • Hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents
  • Intake of drugs with a long half-life (>24 hours) (≤ 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial)
  • Smoker (>= 10 cigarettes or >= 3 cigars or >= 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Known alcohol abuse
  • Known drug abuse
  • Blood donation (≤ 1 month prior to administration)
  • Excessive physical activities (≤ 5 days prior to administration)
  • History of hemorrhagic diatheses
  • History of gastro-intestinal ulcer, perforation or bleeding
  • History of bronchial asthma
  • For female subjects:

    • Pregnancy
    • Positive pregnancy test
    • No adequate contraception e.g. sterilization, IUD (intrauterine device), oral contraceptives
    • Inability to maintain this adequate contraception during the whole study period
    • Lactation period

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02183090    
Other Study ID Numbers: 107.217
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action